NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Adaptam Therapeutics

Adaptam Therapeutics

Private
SpainHealthcare & Life Scienceshttps://adaptamtx.com/

Last Round

Pre Seed

Oct 27, 2025

Total Funding Raised

$3.5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Adaptam Therapeutics is a biotechnology company that develops first-in-class antibody therapies, including antibody-drug conjugates (ADCs) and bispecific antibodies, for solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugatesADCbispecific antibodiesimmunotherapysolid tumorstumor microenvironmentglyco-immune checkpointsbiotech R&Doncology therapeuticstumor-associated macrophagesTAMsdrug discoverypreclinical developmentcancer drug pipelinebiotech licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Adaptam Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Adaptam Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Adaptam Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedOct 27, 2025

Adaptam Therapeutics Investors

Notable investors and investment history

Adaptam Therapeutics investors
InvestorRounds
Caixa Capital RiscPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 23, 2026

    Monthly visitors increased 338% MoM, reaching 1.1K.

Adaptam Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Adaptam Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Adaptam Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSpain
Employee Range6
Year Founded2023
Last FundingOct 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.